Skip to main content
Quest Diagnostics

Leveraging Data Aggregators to Annotate De-identified Genomic Data Derived From Commercial Laboratory Samples to Study COVID-19 Severity

ISPOR 2024

International Society for Pharmacogenomics and Outcomes Research

Atlanta, GA, May 5-8, 2024

Poster presentation: Leveraging Data Aggregators to Annotate De-identified Genomic Data Derived From Commercial Laboratory Specimens to Study COVID-19 Severity

Authors: Dandiker S, Latham A, Tanpaiboon P, Ratajski AM, Bare L, Fesko Y, Joseph V,  Offit K

Specialty: Genetics, Infectious Disease, COVID-19

Related content

Publication
Microfluidic immuno-serolomic assay reveals systems level association with COVID-19 pathology and vaccine protection
Publication
Changes in Newly Identified Cancer Among US Patients From Before COVID-19 Through the First Full Year of the Pandemic
Publication
Linking Statistics With Testing Policy to Manage COVID 19 in the Community
Conference Presentation
The Importance of a Specimen Adequacy Control to Reduce False-Negative Mpox Virus Real-Time PCR Test Results
Audio Podcast
Alternative Specimen Collection Options

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.